- $40 million in BioTime common shares;
- Warrants to purchase BioTime common shares (“ BioTime Warrants”);
- Rights to certain stem cell assets of BioTime, and shares of two BioTime subsidiaries engaged in the development of therapeutic products from stem cells.
|Michael D. West, PhD||Thomas Okarma, PhD, MD|
|Chief Executive Officer||Chief Executive Officer|
|BioTime, Inc.||BioTime Acquisition Corp.|
|Geron Founder||Former Geron CEO|
|Former Geron CEO||(1999-2011)|